Should Israel screen all mothers-to-be to prevent early-onset of neonatal group B streptococcal disease? A cost-utility analysis

Table 2 Summary of costs (NIS at 2010 price levels) and QALY losses of proposed universal GBS screening versus current risk-factor screening

			Incremental
	Current	Proposed	Change
Screening Costs	617,408	3,498,644	2,881,236
Treatment Savings	–614,683	–2,550,420	–1,935,737
lifetime productivity gains	–256,990	–1,068,618	–811,628
Net Cost to Society	–254,266	–120,394	133,872
Mortality QALYs lost	34.97	23.87	–11.10
Morbidity QALYs lost	0.56	0.24	–0.32
Sequellae QALYs lost	1.97	0.81	–1.16
Total QALYS lost	37.50	24.92	–12.58

ISSN: 2045-4015